- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00406016
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
February 8, 2020 updated by: Novartis
A Multi-center, Open-label, Cohort Study to Assess Feasibility, Acute Safety, Tolerability and Pharmacokinetics of 4 Dose Regimens of Continuous Intrathecal ATI355 Infusion and Two Regimen of Repeated Intrathecal Bolus Injections in Acute Spinal Cord Injury Paraplegic and Tetraplegic Patients
This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 6 dose regimens of ATI355 in acute spinal cord injury patients
Study Overview
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Calgary, Canada
- Novartis Investigative Site
-
Montreal, Canada
- Novartis Investigative Site
-
Toronto, Canada
- Novartis Investigative Site
-
Vancouver, Canada
- Novartis Investigative Site
-
-
-
-
-
Bad Wildungen, Germany, 34537
- Novartis Investigative Site
-
Bayreuth, Germany, 09445
- Novartis Investigative Site
-
Bochum, Germany, 44789
- Novartis Investigative Site
-
Hamburg, Germany, 21033
- Novartis Investigative Site
-
Heidelberg, Germany, 69118
- Novartis Investigative Site
-
Karlsbad-Lagensteinbach, Germany, 76307
- Novartis Investigative Site
-
Murnau, Germany, 82418
- Novartis Investigative Site
-
Tuebingen, Germany, 72076
- Novartis Investigative Site
-
Ulm, Germany, 89081
- Novartis Investigative Site
-
-
-
-
-
Zuerich, Switzerland, 8008
- Novartis Investigative Site
-
Zurich, Switzerland, 8008
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria
- Acute spinal cord injury paraplegic and tetraplegic patients with confirmed classification of ASIA A (C5 ≤ lesion ≤ T12; 4-14 days post-injury (i.e. study drug treatment must begin 4-14 days post injury) for paraplegic patients and for those tetraplegic patients who do not require artificial respiration at time of treatment initiation within the 4-14 days time interval. In those tetraplegic patients who still require artificial respiration in the 4-14 days time interval treatment can be initiated up to 60 days post-injury as soon as the patient is weaned off the respiratory machine.)
- Tetraplegic patients who were initially diagnosed as ASIA A (neurologically complete lesion) at screening and turned into ASIA B (neurologically incomplete lesion) at baseline.
- Hemodynamically stable (at baseline).
- For female patients of child bearing potential, written agreement to abstain from intercourse during the first 12 weeks of the study and then subsequent use of a double-barrier local contraception, i.e. intra-uterine device plus condom, or spermicidal gel plus condom for up to one year post study drug treatment. Patients must receive documented counseling on contraceptive measures.
- For Cohort 5: Acute spinal cord injury tetraplegic patients with confirmed classification of ASIA A: Cervical lesions (C5 ≤ lesion ≤ T1). 4-28 days post-injury (i.e. study drug treatment must begin 4-28 days post injury). Tetraplegic patients who are allowed to start treatment are those who either do not require mechanical ventilation or who do not completely depend on mechanical ventilation but show some degree of spontaneous ventilation. Only those modes of ventilation where the patient must initiate all breaths are allowed (e.g. continuous positive airway pressure [CPAP]).
Exclusion criteria
- Complete anatomical transection confirmed by MRI or trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds.
- Magnetic Resonance Imaging (MRI) indicating complete obstruction of the intrathecal space.
- Presence of one of the following:
- multiple spinal cord lesions
- cauda equina damage
- major brachial or lumbar plexus damage/trauma
- significant head trauma (e.g. cortical damage/lesion), or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function or otherwise compromise the validity of the patient's data.
- Other significant preexisting or current systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including human immunodeficiency virus [HIV]) or kidney disease; or active malignancy or any other condition as determined by history or laboratory investigation that could cause a neurological deficit including syphilis, myelopathy, clinically relevant polyneuropathy, etc.
- History of meningitis, meningoencephalitis, epilepsy or life-threatening allergic or immune-mediated reaction.
- History of or current autoimmune disease or an acute episode of Guillain-Barre syndrome.
- Patients with uncontrolled bleeding diathesis and/or on concomitant treatment with coumarin anticoagulant.
- Presence of any unstable medical or psychiatric condition (defined by the Diagnostic and Statistical Manual of Mental Disorders-IV [DSM-IV]) that could reasonably have been expected to subject the patient to unwarranted risk from participation in the study or result in a significant deterioration of the patient's clinical course.
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/ml).
- Hemoglobin levels below 8.0 g/dl and/or patients who required greater than 10 (ten) blood transfusions since the acute injury
- Patients with concomitant treatment with Metamizole from Screening until end of Follow Up phase
- Mechanical ventilation will be allowed for patients in Cohort 5, the patient must not depend completely on the ventilation but should show some degree of spontaneous ventilation. Only those modes of ventilation where the patient must initiate all breaths are allowed (e.g. continuous positive airway pressure [CPAP]).
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility, Safety and Tolerability of a continuous intrathecal (i.t.) infusion or i.t. repeated bolus injections of ATI355 in patients with acute spinal cord injury at every visit and Assessment of serum and CSF pharmacokinetics at predefined visits.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity of ATI355 in acute spinal cord injury patients up to one year.
Time Frame: 1 year
|
1 year
|
Early potential signal of efficacy by the American Spinal Cord Injury Association (ASIA) protocol and pharmacodynamic changes assessed by electrophysiology tests for up to one year.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (ACTUAL)
September 1, 2011
Study Completion (ACTUAL)
September 1, 2011
Study Registration Dates
First Submitted
November 30, 2006
First Submitted That Met QC Criteria
November 30, 2006
First Posted (ESTIMATE)
December 4, 2006
Study Record Updates
Last Update Posted (ACTUAL)
February 11, 2020
Last Update Submitted That Met QC Criteria
February 8, 2020
Last Verified
November 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CATI355A2102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Spinal Cord Injury
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
University of British ColumbiaRecruitingSpinal Cord Injuries | Acute Spinal Cord Injury | Acute Spinal Paralysis | Trauma, Spinal CordCanada
-
Kringle Pharma, Inc.Recruiting
-
AlaMab Therapeutics (Shanghai) Inc.RecruitingAcute Spinal Cord InjuryChina
-
University of KentuckyRecruiting
-
University of British ColumbiaUnited States Department of DefenseRecruitingSpinal Cord Injuries | Acute Spinal Cord InjuryCanada
-
Pharmazz, Inc.Recruiting
-
Ohio State UniversityTerminated
-
Chinese Academy of SciencesThe First Affiliated Hospital of Soochow University; General Hospital of Ningxia... and other collaboratorsUnknownAcute Spinal Cord InjuryChina
-
University of CalgaryHotchkiss Brain Institute, University of Calgary; AANS/CNS Section on Disorders...TerminatedAcute Spinal Cord InjuryUnited States, Canada